MARKET

AKRO

AKRO

Akero
NASDAQ

Real-time Quotes | Nasdaq Last Sale

33.99
-0.62
-1.79%
After Hours: 33.99 0 0.00% 16:00 08/14 EDT
OPEN
34.67
PREV CLOSE
34.61
HIGH
35.12
LOW
32.85
VOLUME
266.05K
TURNOVER
--
52 WEEK HIGH
41.16
52 WEEK LOW
10.78
MARKET CAP
1.15B
P/E (TTM)
-19.0228
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AKRO stock price target is 58.29 with a high estimate of 80.00 and a low estimate of 43.00.

EPS

AKRO News

More
Akero Therapeutics EPS beats by $0.05
Akero Therapeutics (AKRO): Q2 GAAP EPS of -$0.57 beats by $0.05.Cash, equivalents and short-term marketable securities of $102.8MPress Release
Seekingalpha · 2d ago
Akero Therapeutics Q2 EPS $(0.57) Up From $(2.21) YoY
Akero Therapeutics (NASDAQ:AKRO) reported quarterly losses of $(0.57) per share. This is a 74.21 percent increase over losses of $(2.21) per share from the same period last year.
Benzinga · 2d ago
Biotech Bonanza - Second Half Outlook
Seeking Alpha · 07/28 12:24
A Top Contender in the Race for a NASH Drug Drops Out
French biotech Genfit, which had been expected to bring one of the first drugs to market to treat nonalcoholic steatohepatitis, said it is getting out of the race altogether.
Barrons.com · 07/23 15:02
Research Published in Cell Reports Medicine Highlights Potential of Akero Therapeutics' NASH Therapeutic Candidate
Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic, non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance, today announced the publication of data in the journal Cell Reports Medicine from t
PR Newswire · 07/21 15:00
Akero Therapeutics raises $216.4M in stock offering
Akero Therapeutics (NASDAQ:AKRO) closes upsized public offering at gross proceeds of ~$216.4M for 6M shares; underwriters' option to purchase additional sh
seekingalpha · 07/11 01:18
Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
PR Newswire · 07/10 21:05
The Daily Biotech Pulse: FDA Nod For Osmotica, OptiNose Strikes Co-promotion Deal, Orphan Drug Designation For AnaptysBio
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8)
Benzinga · 07/09 12:09

Industry

Biotechnology & Medical Research
-0.54%
Pharmaceuticals & Medical Research
-0.38%

Hot Stocks

Symbol
Price
%Change

About AKRO

Akero Therapeutics, Inc. is a clinical-stage biotechnology company that is focused on developing and commercializing treatments for serious metabolic diseases. The Company is engaged in nonalcoholic steatohepatitis (NASH), a disease without any approved therapies. NASH is a severe form of nonalcoholic fatty liver disease, or NAFLD, characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, cancer and death. The Company’s lead product candidate, AKR-001, which the Company is developing as a treatment for patients with NASH, is an analog of fibroblast growth factor 21 (FGF21). FGF21 is an endogenously-expressed hormone that regulates metabolism of lipids, carbohydrates and proteins throughout the body.
More

Webull offers kinds of Akero Therapeutics Inc stock information, including NASDAQ:AKRO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKRO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AKRO stock methods without spending real money on the virtual paper trading platform.